Back to all articles
Quality Systems6 min read

Cosmetic Adverse-Event Records Are Becoming Inspection Evidence

MoCRA makes cosmetic adverse-event reporting and recordkeeping an evidence discipline. Learn how to design intake, seriousness screening, product traceability, signal review, and retrievable case files.

By Melita Ball

Cosmetic safety reporting illustration showing adverse-event case records and product traceability.

Adverse-event handling is now an evidence discipline

Under MoCRA, responsible persons must report serious adverse events associated with cosmetic products in the United States and maintain adverse-event records. That obligation changes what internal complaint handling has to accomplish. It is no longer enough to answer a consumer, replace a product, and close the contact.

The practical difficulty is that cosmetic adverse-event information often arrives through channels built for customer service rather than regulatory decision-making. Reports may come through retailer portals, social media, call centers, e-commerce reviews, professional accounts, or distributor emails. Each channel captures different details, and few capture the details a safety reviewer needs.

Strong programs solve this at intake, not at reporting. If the record does not capture the product identity, event description, seriousness indicators, and follow-up attempts, a downstream reviewer cannot make a defensible determination.

Design intake around the safety question

Build one controlled intake dataset and require every channel to feed it. The dataset should capture the reporter type and contact permission, the date the company became aware, the product name and identifiers, batch or lot when available, the purchase and use context, a verbatim description of the event, onset and duration, medical attention sought, outcome, concomitant products, and any images or documentation provided.

Seriousness screening

Screening is a defined assessment, not an informal opinion. Document the criteria the organization uses, apply them consistently, and record the basis for the conclusion. Where seriousness cannot be determined because information is missing, say so explicitly and record the follow-up attempts made to close the gap.

Reasonable follow-up should be planned, time-bound, and logged. A record showing three documented contact attempts with dates is far stronger than a note stating the consumer did not respond.

Product identification and traceability

The event record is only as useful as the product link behind it. Connect the report to the specific formulation version, fill site, batch, and distribution window when the information exists. That link is what allows the safety team to look for patterns and the operations team to evaluate whether a manufacturing variable is involved.

When lot information is unavailable, capture what is known — purchase date, retailer, packaging description, or photographs — and record the limitation. Undocumented uncertainty later reads as an unexamined gap.

Connect events to the rest of the quality system

An adverse-event record should be able to trigger other controlled processes. Define the criteria that route an event to safety substantiation review, formulation assessment, label review, supplier investigation, nonconformance, or corrective action. Define who owns each determination and what evidence closes it.

Signal review matters as much as individual case handling. A single mild irritation report may not indicate a problem. A cluster in one batch, one region, or one product variant may. Periodic aggregate review should be scheduled, documented, and connected to the facility and formulation records that would support or refute a hypothesis.

Record retention deserves specific attention. Retention periods, access controls, and the ability to retrieve a complete case file — including attachments and follow-up correspondence — should be tested rather than assumed.

Test the file before someone asks for it

Choose one recent report and ask an independent reviewer to reconstruct it end to end. Can they identify when the company became aware, what was reported, how seriousness was assessed, what follow-up occurred, what product records were reviewed, what decision was made, and who approved it?

If the answer requires a conversation with the person who handled the case, the record is not yet inspection-ready. The goal is a case file that speaks for itself, in a system where the next case is handled the same way.

Teams building this discipline can connect it to broader corrective action practice and a connected quality system so that consumer safety information, product records, and decisions stay in one traceable chain.

From the platform

Build audit-ready compliance without the spreadsheets.

IntelaSolve is the compliance infrastructure platform unifying regulatory, clinical, quality, and post-market operations for medical device and pharmaceutical teams.